Clinical trials
Polyneuropathies clinical trials
Below are recruiting polyneuropathies clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06859099Enrolling by invitationPhase 3
Long-term safety study of Riliprubart for CIDP
This study checks the long-term safety and how well riliprubart works for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for those who have already taken riliprubart in a previous study.
Homewood, AlabamaAges 18 years+ - NCT06745011Enrolling by invitation
Parkinson's signs in people with nerve damage
This study looks for early signs of Parkinson's disease in people who have nerve damage in their hands and feet (polyneuropathy) with no known cause, along with drops in blood pressure when standing up. It aims to understand if these early symptoms might predict future Parkinson's.
Aarhus, JutlandAges 18–85 - NCT06672237RecruitingPhase 3
Study of NTLA-2001 for hereditary ATTR amyloidosis with nerve damage
This study is testing a new gene-silencing treatment called NTLA-2001 for people with hereditary ATTR amyloidosis that causes nerve damage. It works by stopping the body from making a faulty protein that builds up and harms nerves.
Buenos AiresAges 18–85 - NCT06605612Enrolling by invitation
Falls risk test for people with muscle and nerve conditions
This study is creating a test to predict falls in people with neuromuscular disorders. You will fill out a questionnaire about your fall risk.
München, BavariaAges 18–65 - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
La Jolla, CaliforniaAges 18–75 - NCT06377033Recruiting
Using health records to advance genomic medicine for all
This study uses electronic health records to learn how to improve genomic medicine across a diverse health system. It may help make DNA-based healthcare more accessible and effective for people with certain conditions.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06299748Recruiting
Efgartigimod safety study for pregnancy and breastfeeding
This study is for women who have taken efgartigimod (a medicine for certain autoimmune conditions) right before or during pregnancy, or while breastfeeding. Researchers will monitor moms, fetuses, and babies to check for side effects and ensure safety.
Morgantown, West VirginiaAges Any age - NCT06186479RecruitingPhase 3
Testing Aconite Pain Oil for Chemotherapy Nerve Damage
This trial tests a pain oil made from aconite (a plant extract) to see if it can prevent or reduce nerve damage and pain caused by chemotherapy. It is for people with solid tumors who are starting treatment with taxane or platinum drugs.
MannheimAges 18–100 - NCT06124586Recruiting
Early angioplasty for diabetic foot ulcers
This trial tests if an early procedure to open blocked leg arteries (angioplasty) helps heal foot ulcers in people with type 2 diabetes. It aims to improve blood flow and prevent amputation.
DüsseldorfAges 18 years+ - NCT03717844Recruiting
Registry for adults with plasma cell disorders
This study is a registry that collects information about adults with plasma cell disorders (conditions involving abnormal antibody-producing cells). It may help researchers understand these diseases better and improve future care by tracking patients over time.
Chapel Hill, North CarolinaAges 18 years+ - NCT05697861Enrolling by invitation
Follow-up study for people previously treated with NTLA-2001
This study checks how people are doing long-term after receiving NTLA-2001 in an Intellia clinical trial. If you previously took part and agree to be followed, this may help the researchers understand lasting safety and effects.
ParisAges 18 years+ - NCT05639478Recruiting
Foot care and exercise program for people with diabetes
This trial tests whether a structured foot-care and exercise program in primary care helps adults with diabetes. It may help you stay more active and reduce foot problems by teaching daily care and safe movement.
Limeira, São PauloAges 18 years+ - NCT05584631RecruitingPhase 1
Switching IVIG to weekly SCIG for CIDP treatment
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
New Brunswick, New JerseyAges 18–65 - NCT05327114RecruitingPhase 2/Phase 3
Nipocalimab for adults with chronic inflammatory CIDP nerve disease
This trial tests nipocalimab (an antibody medicine) to improve symptoms and control activity in chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. It may help reduce disease activity and disability, while checking safety.
Centennial, ColoradoAges 18 years+ - NCT05283993Recruiting
Hospital study following people with plasma cell disorders
This is a hospital-based study that follows people with plasma cell disorders to better understand these conditions. It mainly gathers information from patients who are confirmed to have one of several related diseases.
BeijingAges Any age - NCT05040373Recruiting
Patisiran pregnancy safety monitoring program
This program monitors the safety of the drug patisiran during pregnancy. If you have received patisiran around the time of pregnancy, it may help track any effects on you and your baby.
Iowa City, IowaAges Any age - NCT04929236RecruitingPhase 3
Testing different PANZYGA doses for children with CIDP
This Phase 3 study compares different dose schedules of PANZYGA (immune-globulin) in children with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It aims to find a dosing plan that is both safe and effective for improving symptoms and function.
Birmingham, AlabamaAges 2–17 - NCT04881682RecruitingPhase 2
Testing blood-cleansing vs immunoglobulin for CIDP
This Phase 2 study compares a blood-cleansing treatment (immunoadsorption) with standard immune-boosting treatment (intravenous immunoglobulins) for chronic inflammatory demyelinating polyneuropathy (CIDP). It may help people whose steroid treatment did not work well, or who cannot take steroids.
Ulm, Baden-WurttembergAges 18 years+ - NCT04153422RecruitingPhase 2
IVIG for small fiber nerve pain with specific antibody tests
This trial studies whether IVIG (an immune therapy made from donated antibodies) can reduce pain from autoimmune small fiber neuropathy. You may be a candidate if your tests show certain autoantibodies (TS-HDS, FGFR3, or Plexin-D1) and your symptom scores are high enough.
Glenview, IllinoisAges 18 years+ - NCT03810768Recruiting
Metabolomics study of ICU-acquired weakness after surgery
This study looks at blood and body chemistry (called metabolomics) to understand and possibly predict muscle weakness that can happen in the ICU after surgery. It may help researchers find better ways to prevent or monitor this problem.
Vienna, State of ViennaAges 18 years+ - NCT03684018RecruitingPhase 4
Testing two doses of Privigen for children with CIDP
This study tests whether two different dose levels of Privigen (a type of immune blood treatment) are safe and effective for children and teens with CIDP. It may help improve nerve-related symptoms in people whose CIDP has been confirmed or is being evaluated as likely.
Phoenix, ArizonaAges 2–17
Hear when a new Polyneuropathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for polyneuropathies?
- Yes. Clin2 currently lists 69 recruiting polyneuropathies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a polyneuropathies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a polyneuropathies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.